Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 7/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.55 |
| ▸ | CASP7 | P55210 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | AKT2 | P31751 | 2/20 | 0.53 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.53 |
| ▸ | CDC7 | O00311 | 1/20 | 0.52 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.52 |
| ▸ | SCD | O00767 | 1/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1791316 | 0.82 | HTR3E (0.51) | MAPTRPS6KB1HTR3EHTR3BALDH1A1 | |
| SCHEMBL2298188 | 0.82 | MAPT (1.00) | MAPTRPS6KB1HTTHSD17B10TSHR | |
| SCHEMBL2301186 | 0.81 | HTT (0.75) | MAPTRPS6KB1HTTHSD17B10TSHR | |
| SCHEMBL6755685 | 0.78 | HTT (0.86) | MAPTRPS6KB1HTTHSD17B10TSHR | |
| SCHEMBL29898244 | 0.78 | HTT (0.86) | MAPTRPS6KB1HTTHSD17B10TSHR | |
| SCHEMBL12048138 | 0.78 | HTT (0.86) | MAPTRPS6KB1HTTHSD17B10TSHR | |
| SCHEMBL1789757 | 0.77 | RPS6KB1 (0.69) | MAPTRPS6KB1AKT2HTR3EHTR3B | |
| SCHEMBL2298278 | 0.76 | HTT (1.00) | MAPTRPS6KB1HTTHSD17B10TSHR | |
| SCHEMBL12048123 | 0.76 | HTT (1.00) | MAPTRPS6KB1HTTHSD17B10TSHR | |
| SCHEMBL1790717 | 0.76 | RPS6KB1 (0.70) | MAPTRPS6KB1HTTLMNAAKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111643496-A | Methods of using MEK inhibitors | 埃克塞利希斯股份有限公司 | 2020-09-11 | — | — | CN | disclosed |
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-8076338-B2 | Such as 6-(4-phenylpiperazin-1-yl)-9H-purine; cell proliferation/differentiation | EXELIXIS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076338-B2 | Such as 6-(4-phenylpiperazin-1-yl)-9H-purine; cell proliferation/differentiation | EXELIXIS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-7999006-B2 | Anticancer agents; mitogen-activated protein kinases (MEK) | EXELIXIS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| CN-101605540-A | Methods of using MEK inhibitors | EXELIXIS INC (US) | 2009-12-16 | — | — | CN | disclosed |
| EP-2101759-A1 | METHODS OF USING MEK INHIBITORS | Exelixis, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | disclosed |
| WO-2008076415-A1 | METHODS OF USING MEK INHIBITORS | EXELIXIS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | MAPT 3423/4885RPS6KB1 700/4885HTT 4789/4885 |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | AKT3, RPS6KA3, CDK3 | MAPT 4051/4885RPS6KB1 13/4885HTT 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.